Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Calliditas Therapeutics in connection with a directed share issue
Mandate

Vinge advises Calliditas Therapeutics in connection with a directed share issue

August 17, 2021 Capital Markets and Public M&A

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with a directed share issue whereby the company will raise proceeds of approximately SEK 324 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström and Benjamin Vafaeian.

Related

Vinge advises Borgo in connection with its inaugural issuance of primary capital instruments (AT1)

 Vinge has advised Borgo AB (publ) in connection with its successful issuance of primary capital instruments (so called “AT1 bonds”) in the amount of SEK 350 million with a floating rate coupon of 3-month STIBOR + 390 basis points.
January 29, 2026

Vinge advises J Bil in conjunction with the acquisition of Appelskog Bil AB

 Vinge has advised the buyer J Bil AB in conjunction with the acquisition of all shares in Appelskog Bil AB.
January 29, 2026

Vinge has advised United Lithium Corp. in connection with the acquisition of Swedish Minerals AB

 United Lithium is an exploration & development company focused on the global demand for lithium, uranium and rare earth elements.
January 29, 2026